BioLife Solutions

BioLife Solutions' stock rose to a new 52-week high of $35.36, nearly 98% above its yearly low; it gained 44% over the past year and 57% in the last six months. Data from InvestingPro point to an overbought RSI and currently rate the stock as overvalued. TD Cowen downgraded the stock from "Buy" to "Hold" after the announcement of an acquisition by Repligen, cutting the price target to $31; the transaction is expected to be paid about two-thirds in stock and one-third in cash. » More on de.investing.com

BioLife Solutions shares rose to a 52-week high of $33.18 and are currently trading near that level; market capitalization is about $1.61 billion. The company reported Q1 2026 revenue of $27.5 million, beating analysts' estimates, while EPS remained flat at $0.02. Repligen announced a planned takeover of BioLife Solutions at $31 per share (two-thirds stock, one-third cash), prompting TD Cowen to cut its rating to "Hold" and lower its price target. Analysts see strong growth and a return to profitability but warn of possible overvaluation. » More on de.investing.com

BioLife Solutions shares rose to a 52-week high of $32.24, well above the year low of $17.86. In Q1 2026 the company reported revenue of $27.5 million, beating analysts' estimates, while EPS was $0.02. Repligen announced a takeover offer of $31 per share (two-thirds stock, one-third cash), after which TD Cowen downgraded the rating to "Hold." InvestingPro praises the revenue growth and assigns a "VERY GOOD" grade, but in a fair-value analysis points to a possible overvaluation. » More on de.investing.com